Linvoseltamab During Maintenance Therapy

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

What's the purpose of the trial?

The researchers also want to find out the effects that linvoseltamab has on participants and participants' condition.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
32
Last Updated

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Linvoseltamab is a bispecific antibody being tested for use in multiple myeloma that targets BCMA on cancer cells and CD3 on T-cells . 

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cohort 1 - Linvoseltamab Treatment Group

Accepting patients

Cohort 2 - Lenalidomide Treatment Group

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.